Press Releases

<<  Back

  View printer-friendly version

Aimmune to Participate in Three Investor Conferences in September

BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in September:

Event: 2019 Wells Fargo Healthcare Conference
Date: Wednesday, September 4, 2019
Presentation Time: 8:30 a.m. Eastern Time
Location: Boston, MA
Presenter: Eric Bjerkholt, Chief Financial Officer

Event: Baird 2019 Global Healthcare Conference
Date:Thursday, September 5, 2019
Presentation Time: 11:25 a.m. Eastern Time
Location:New York, NY
Presenter: Jayson Dallas, M.D., President and Chief Executive Officer

Event:Morgan Stanley 17th Annual Global Healthcare Conference
Date: Tuesday, September 10, 2019
Presentation Time: 4:05 p.m. Eastern Time
Location:New York, NY
Presenter: Eric Bjerkholt, Chief Financial Officer

A live webcast of each fireside chat will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Replays will be available following each webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational, complex biologic product, AR101, is being developed as a treatment to reduce the frequency and severity and adverse events following exposure to peanut. The BLA for AR101 is under review by the FDA, which granted AR101 Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The Allergenic Products Advisory Committee (APAC) of the FDA will review the BLA for AR101 at its meeting scheduled for September 13, 2019. Aimmune initiated a randomized phase 2 clinical trial of AR201 for the treatment of egg allergy in August 2019. For more information, please see www.aimmune.com.

Source: Aimmune Therapeutics, Inc.

Investors:
DeDe Sheel
(917) 834-1494 or
dsheel@aimmune.com

Media:
Jerica Pitts
(312) 858-3469 or
jpitts@w2ogroup.com